Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cara McLeod

Rheumatology Marietta, GA Doctor of Osteopathy

NPI 1205246246 CMS profile 5703323

400 Tower Rd Ne Ste 160, Marietta, GA 30060

Open in the dashboard

General payments

$5,560

258 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cara McLeod of Marietta, GA is reported in the CMS Open Payments database as having received $5,560 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,437 82
2024 General $909 47
2023 General $1,239 58
2022 General $1,037 56
2021 General $96 5
2020 General $99 1
2019 General $743 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cara McLeod
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Cara McLeod were reported at $1,437. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Cara McLeod Rheumatology median Middle half National median
2019 $743 $744 $153–$2,687 $163
2020 $99 $462 $98–$2,027 $114
2021 $96 $531 $101–$2,153 $132
2022 $1,037 $627 $125–$2,303 $149
2023 $1,239 $741 $145–$2,524 $160
2024 $909 $830 $166–$2,660 $164
2025 $1,437 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,854 61 payments
  2. Amgen Inc. $774 51 payments
  3. Novartis Pharmaceuticals Corporation $702 36 payments
  4. Janssen Biotech, Inc. $440 17 payments
  5. GlaxoSmithKline, LLC. $327 25 payments
  6. UCB, Inc. $242 14 payments
  7. AstraZeneca Pharmaceuticals LP $239 10 payments
  8. Mallinckrodt Hospital Products Inc. $169 6 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $141 7 payments
  10. Aurinia Pharma U.S., Inc. $106 4 payments
  11. Other $565 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,445 255 payments
  2. Education $115 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $973 40 payments
  2. TREMFYA $440 17 payments
  3. COSENTYX Dermatology $396 20 payments
  4. SKYRIZI $383 15 payments
  5. BENLYSTA $327 25 payments
  6. COSENTYX Immunology $306 16 payments
  7. Otezla $269 21 payments
  8. SAPHNELO $239 10 payments
  9. TAVNEOS $235 13 payments
  10. HUMIRA $225 4 payments
  11. Other $2,111 107 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

945

Median for Rheumatology: 1,511

Drug cost

$730,903

Median for Rheumatology: $1,139,948

Branded share of claims

31%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 63 $426,754
Enbrel Sureclick Etanercept Brand 19 $153,223
Orencia Abatacept Brand 16 $93,239
Prolia Denosumab Brand 20 $34,202
Hydroxychloroquine Sulfate Generic 143 $4,951
Leflunomide Generic 50 $4,145
Mycophenolic Acid Mycophenolate Sodium Brand 12 $3,360
Mycophenolate Mofetil Generic 22 $3,181
Methotrexate Methotrexate Sodium Brand 150 $2,990
Prednisone Generic 204 $2,089

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$64,006

Medicare's payments for the services billed

Medicare patients

171

Average age 73

Services billed

1,497

121 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Osteoporosis 33%
COPD 25%
Depression 25%
Diabetes 22%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $208
$208 — —
RINVOQ
  • AbbVie, Inc. $133
$133 — —
TREMFYA
  • Janssen Biotech, Inc. $63
$63 — —
LUPKYNIS
  • Aurinia Pharma U.S., Inc. $56
$56 — —
SKYRIZI
  • AbbVie, Inc. $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record